StockNews.com started coverage on shares of Nabriva Therapeutics (NASDAQ:NBRV – Free Report) in a research report report published on Thursday morning. The firm issued a hold rating on the biotechnology company’s stock.
Nabriva Therapeutics Stock Performance
The stock has a market cap of $45.46 million, a price-to-earnings ratio of -0.07 and a beta of 1.53. Nabriva Therapeutics has a 12-month low of $1.22 and a 12-month high of $8.45. The company’s 50-day simple moving average is $0.14. The company has a quick ratio of 0.52, a current ratio of 0.85 and a debt-to-equity ratio of 0.12.
About Nabriva Therapeutics
Featured Articles
- Five stocks we like better than Nabriva Therapeutics
- 2 Fintech Stocks to Buy Now and 1 to Avoid
- Bumble’s Valuation Hits an All-Time Low, Can Its Fortunes Change?
- Procter & Gamble (NYSE:PG) Pulls Back After Shaky Guidance
- MarketBeat Week in Review – 8/12 – 8/16
- Stock Ratings and Recommendations: Understanding Analyst Ratings
- JD.com Earnings Surprise: China’s Outlook Better Than Expected
Receive News & Ratings for Nabriva Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Nabriva Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.